Search company, investor...
Search

Founded Year

2017

Stage

Series C | Alive

Total Raised

$121.85M

Last Raised

$70M | 5 mos ago

Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About AI Medical Service

AI Medical Service seeks to develop a system that supports an endoscopist's diagnosis of the digestive tract, including the esophagus, stomach, and intestines. The company's software focuses on signs of cancer in gastrointestinal organs, including the esophagus, stomach, and intestines, with the goal of reducing the number of hours doctors and other health professionals need to spend going over scans. It was founded in 2017 and is based in Tokyo, Japan.

AI Medical Service Headquarters Location

Hareza Tower 11F 1-18-1 Higashiikebukuro, Toshima-ku

Tokyo, 170-0013,

Japan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

AI Medical Service's Products & Differentiation

See AI Medical Service's products and how their products differentiate from alternatives and competitors

  • Gastro AI (tentative)

    This is the product of endoscopic AI to classify early gastric cancer. This will be launched in next spring.

Research containing AI Medical Service

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned AI Medical Service in 2 CB Insights research briefs, most recently on Feb 16, 2022.

Expert Collections containing AI Medical Service

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AI Medical Service is included in 7 Expert Collections, including Digital Health.

D

Digital Health

21,952 items

Startups recreating how healthcare is delivered

A

Artificial Intelligence

9,391 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

8,687 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,418 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

AI Medical Service Patents

AI Medical Service has filed 3 patents.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Digestive system
  • Digestive system surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/11/2018

3/8/2022

Digestive system, Artificial neural networks, Digestive system surgery, Infectious causes of cancer, Inflammations

Grant

Application Date

5/11/2018

Grant Date

3/8/2022

Title

Related Topics

Digestive system, Artificial neural networks, Digestive system surgery, Infectious causes of cancer, Inflammations

Status

Grant

Latest AI Medical Service News

Japon : SoftBank Robotics; Saint-Gobain ; AI Medical Service relève

May 13, 2022

CANVIEW Partager Pepper © Softbank Rbotics SoftBank Robotics Group se déleste en France. La division de robots du conglomérat télécom japonais cède sa filiale française SoftBank Robotics Europe (SBRE, anciennement Aldebaran) à l’allemand United Robotics Group (URG), en échange d’une participation de 24,9 % dans URG. Les termes financiers demeurent confidentiels. Basé à Paris, SBRE, se revendiquant leader de la robotique humanoïde, fabrique des célèbres robots comme Pepper et Nao. Implanté à Essen en Allemagne, URG, employant plus de 300 personnes principalement basées en Europe (Allemagne, France, Autriche), est devenu le distributeur principal sur le marché européen en octobre 2021, en charge des ventes, du service et de la maintenance. SBRE reprendra surtout son nom d’origine Aldebaran et le directeur général Xavier Lachérade continuera à diriger l'entreprise. Fondée en 2005 par Bruno Maisonnier, elle fabrique et commercialise des robots humanoïdes sous les marques : Nao, Romeo ou encore Pepper. Pour rappel, en 2008 et en 2011, elle s’était entourée respectivement des fonds comme Isource (Sofimac Innovation), Innovation Capital, Intel Capital ainsi que Omnes Capital, à travers deux tours de table de 5 et 9,1 M€. En 2012, SoftBank s’était emparé de la majorité du capital d’Aldebaran Robotics, trois ans plus tard, il avait même augmenté sa part de 80 % à 95 %. Saint-Gobain optimise son positionnement © Saint-Gobain La blue chip français a signé des accords définitifs pour céder au groupe japonais Shinagawa Refractories Corporation, conseillé par Houlihan Lokey, certaines de ses activités céramiques au Brésil et aux États-Unis, pour 70 M€. Le sites brésiliens et américains emploient respectivement plus de 300 personnes et 50 personnes pour un chiffre d’affaires de 79 M$ et 9 M$. La cession devrait être finalisée à la fin 2022 ou au début 2023. En parallèle, le groupe coté français a finalisé deux acquisitions dans les Solutions de Haute Performance : le sud-coréen Global SFC et l’américain Monofrax LLC, représentant environ 20 M€ de chiffre d’affaires annuel. Saint-Gobain a enregistré pour 2021 un chiffre d'affaires de 44,2 Md€ et un résultat net à 2,61 Md€. Et aussi : © AI Medical Service SoftBank Vision Fund 2 a mené un troisième tour de table de 8 milliards de yens (70 M$) pour AI Medical Service, société de technologie médicale basée à Tokyo. Les investisseurs existants ont remis au pot comme Globis Capital Partners, World Innovation Lab (WiL) et Incubate Fund. Fondée en septembre 2017 et dirigée par Tomohiro Tada, la société japonaise développe une solution logicielle dans le diagnostic endoscopique basée sur l'intelligence artificielle (IA), qui aide à détecter le cancer gastrique, avec une équipe de 51 personnes. Depuis sa création, elle a levé au total 13,6 milliards de yens (104,4 M$).

AI Medical Service Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AI Medical Service Rank

  • When was AI Medical Service founded?

    AI Medical Service was founded in 2017.

  • Where is AI Medical Service's headquarters?

    AI Medical Service's headquarters is located at Hareza Tower 11F, Tokyo.

  • What is AI Medical Service's latest funding round?

    AI Medical Service's latest funding round is Series C.

  • How much did AI Medical Service raise?

    AI Medical Service raised a total of $121.85M.

  • Who are the investors of AI Medical Service?

    Investors of AI Medical Service include World Innovation Lab, Incubate Fund, Globis Capital Partners, SoftBank Group, Ryoyo Electro Corporation and 9 more.

  • Who are AI Medical Service's competitors?

    Competitors of AI Medical Service include NEC and 4 more.

  • What products does AI Medical Service offer?

    AI Medical Service's products include Gastro AI (tentative).

You May Also Like

Lifetrack Medical Systems Logo
Lifetrack Medical Systems

Lifetrack Medical Systems is a Singapore and Philippines-based health tech startup that develops and deploys a scalable, fully distributed medical imaging software designed for affordable access for the two-thirds of the world’s population that currently lack it. The software has been used across Asia, North America, Europe, and Africa to allow customers to scale and integrate their radiology operations.

Xeltis Logo
Xeltis

Xeltis is a clinical-stage company developing medical devices that enable cardiovascular restoration. The Xeltis medical device platform comprises of bioabsorbable heart valves and blood vessels that are designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. Xeltis was founded in 2006 and is based in Zurich, Switzerland.

Diabetes Neuromathix Logo
Diabetes Neuromathix

Diabetes Neuromathix is an AI/Medtech startup building genuinely machine-intelligent artificial pancreas software suitable for the people who need it most: people with 'brittle' type-1 diabetes (T1D), who suffer from large-scale swings in blood glucose levels on a daily basis.

C
Ceretrieve

Ceretrieve designs and develops neurothrombectomy system with integrated embolic protection for ischemic stroke endovascular treatment. The company provides physicians easy-to-use devices to prevent distal embolization during thrombectomy procedures for better treatment efficiency and offers patients improved clinical outcomes. It is based in Misgav, Israel.

Better Body Image Logo
Better Body Image

Better Body Image is a mobile app that visually shows what users look like after weight loss and creates a personalized exercise and eating plan so they can achieve goals and realize better body image.

B
Body Vision Medical

Body Vision Medical is a software and medical device company specializing in augmented real-time fusion imaging, artificial intelligence and intra-body navigation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.